Skip to main content
SpringerLink
Log in

Nicergoline in senile dementia of alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

In a double-blind, placebo-controlled study on the therapeutic efficacy and central effects of nicergoline, an ergot alkaloid with metabolic, antithrombotic and vasoactive action, 112 patients with mild to moderate dementia, diagnosed according to DSM IIIR criteria criteria (MMS 13-25), living in pensioners' homes, were included. Fifty-six were subdiagnosed as senile dementia of the Alzheimer type (SDAT), 56 as multi-infarct dementia (MID), based on computed tomography and Hachinski scores (≤49 SDAT, ≥7 MID). They received, after 2 weeks' run-in period (placebo), randomized for 8 weeks either 2 × 30 mg nicergoline (NIC) or 2 × 1 placebo (PLAC) orally. The four subgroups (SDAT/NIC, SDAT/PLAC, MID/NIC, MID/PLAC; 4 × 28 patients) were comparable in regard to age and sex. Only four, four, four and two patients of the respective groups did not finish the study for minor reasons. Confirmatory statistical analysis demonstrated in the target variable — the Clinical Global Impression (CGI) — a significant superiority of NIC over PLAC in both the SDAT and MID groups. Global improvement (CGI item 2) was seen in both nicergoline subgroups (3 and 3), while no changes occurred under placebo (4 and 4, respectively). The responder versus non-responder ratio was in the SDAT/NIC group 16/8, versus 8/16 in the SDAT/PLAC group (χ2=4.1,P=0.04); in the MID/NIC group 17/7, versus 7/19 in the MID/PLAC group (χ2=7.96,P<0.005). Furthermore, there was a significant improvement of the Mini-Mental State and the SCAG score in both the MID and SDAT group after 8 weeks of nicergoline, which was significantly superior to the minimal improvement or no change in placebo-treated SDAT and MID patients. EEG mapping demonstrated in NIC-treated SDAT and MID patients a significant decrease in delta and theta, increase in alpha 2 and beta activity and an acceleration of the centroid of the total power spectrum as compared with pretreatment, while opposite changes occurred in PLAC-treated SDAT and MID patients. The differences between PLAC and NIC reached the level of statistical significance. Event-related potential (ERP) recordings demonstrated a significantly shortened P300 latency under NIC treatment in both SDAT and MID patients, while there was a trend towards lengthening under PLAC. Thus, nicergoline improved vigilance and information processing at the neurophysiological level, which leads at the behavioural level to clinical improvement both in degenerative and vascular dementia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abt K (1988) Descriptive data analysis (DDA) in quantitative EEG studies. In: Samson-Dollfus D, Guieu JD, Gotman J, Etevenon P (eds) Statistics and topography in quantitative EEG. Elsevier, Amsterdam, pp 150–160

    Google Scholar 

  • American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, third edition, revised, American Psychiatric Association, Washington, DC

    Google Scholar 

  • Anderer P, Saletu B, Kinsperger K, Semlitsch H (1987) Topographic brain mapping of EEG in neuropsychopharmacology — part I. Methodological aspects. Meth Find Exp Clin Pharmacol 9 [6]:371–384

    Google Scholar 

  • Anderer P, Semlitsch HV, Saletu B, Barbanoj MJ (1992) Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res 45:79–93

    PubMed  Google Scholar 

  • Arrigo A, Moglia A, Borsotti L, Massarini M, Alfonsi E, Battaglia A, Sacchetti GA (1982) Double-blind, placebo-controlled, cross-over trial with nicergoline in patients with senile dementia. Int J Clin Pharm Res 2[1]:33–41

    Google Scholar 

  • Bartels PH, Subach JA (1976) Automated interpretation of complex scenes. In: Preston E, Onoe M (eds) Digital processing of biomedical imagery. Academic Press, New York, pp 101–114

    Google Scholar 

  • Battaglia A, Bruni G, Ardia A, Sacchetti G (1989) Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. Jags 37:295–302

    Google Scholar 

  • Bente D, Glatthaar G, Ulrich G, Lewinsky M (1979) Quantitative EEG-Untersuchungen zur vigilanzfördernden Wirkung von Nicergolin. Ergebnisse einer Doppelblindstudie bei gerontopsychiatrischen Patienten. Arzneimittelforschung 29:1804–1808

    PubMed  Google Scholar 

  • Benzi G, De Bernardi M, Manzo L, Ferrara A, Panceri P, Arrigoni E, Berte F (1972) Effect of lysergide and nicergoline on glucose metabolism investigated on the dog brain isolated in situ. J Pharm Sci 61[3]:348–352

    PubMed  Google Scholar 

  • Benzi G, Arrigoni E, Pastoris O, Villa RF, Dagani F, Marzatico F, Agnoli A (1979) Effect of some drugs on cerebral energy state during and after hypoxia and complete or incomplete ischemia. Biochem Pharmacol 28:435–439

    Article  PubMed  Google Scholar 

  • Berner, P (1977) Psychiatrische Systematik. Huber, Bern - Stuttgart - Wien

    Google Scholar 

  • Borromei A (1989) Adjuvant therapy for Parkinson's disease. Preliminary data of a multicentre study with nicergoline. Funct Neurol 4:63–67

    Google Scholar 

  • Chandra P, Paul A (1985) The effects of nicergoline and other vasoactive substances on molecular biological processes in the brain and their effects on the learning abilities of rats. In: Heidrich H (ed) Proof of therapeutic effectiveness of nootropic and vasoactive drugs. Springer, Berlin, Heidelberg, New York, Tokyo, pp 119–130

    Google Scholar 

  • Dolce G, Cecconi V, Zamponi A, Zylbergmann R, Maggi L, Battaglia A (1985) Terapia farmacologica associata a riabilitazione neuromotoria nel paziente: un nuovo approccio metodologico per la valutazione clinica di farmaci nootropi. Giorn Geront (suppl) 62:55–63

    Google Scholar 

  • Duffy FH, Bartels PH, Burchfield JL (1981) Significance probability mapping: An aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol 51:455–462

    Article  PubMed  Google Scholar 

  • Ehrly AM, Landgraf H (1985) Einfluß von Nicergolin auf die Filtrabilität hyperosmolaren Blutes. In: Heidrich H (ed) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen: Fortschritte in der klinischen und experimentellen Nicergolin-Forschung. Springer, Berlin, Heidelberg, New York, Tokyo, S 189

    Google Scholar 

  • Fischhof PK, Wagner G, Litschauer G, Apecechea M, Hiersemenzel R, Röhmel J, Rüther E, Hoffmeister F, Schmage N (1989) Therapeutic results with nimodipine in primary degenerative dementia and multi-infarct dementia. In: Bergener M, Reisberg B (eds) Diagnosis and treatment of senile dementia. Springer, Berlin, pp 350–359

    Google Scholar 

  • Fischhof PK, Saletu B, Rüther E, Litschauer G, Möslinger-Gehmayr R, Herrmann WM (1992) Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology 26:65–70

    PubMed  Google Scholar 

  • Folstein MF, Folstein SE, Mc Hugh PR (1975) Mini Mental State: a practical method for grading the cognitive state of patients for the clinican. J Psychiatr Res 12:189–198

    Article  PubMed  Google Scholar 

  • Gasser T, Bächer P, Möcks J (1982) Transformation towards the normal distribution of broad band spectrum parameters of the EEG. Clin Neurophysiol 43:119–124

    Google Scholar 

  • Gessner B, Thomalske G, Musil J, Jobst E (1979) Bestimmung der EEG-Aktivität und der Bioverfügbarkeit von Nicergolin mittels quantitative EEG-Analysen. Arzneimittelforschung 29:1282–1287

    PubMed  Google Scholar 

  • Granata M, Dondero D, Tomasinelli R (1984) Studio clinico controllato della nicergolina dell' insufficienza cerebrale senile. Atti Accad Med Lomb 39:33–40

    Google Scholar 

  • Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RR, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637

    PubMed  Google Scholar 

  • Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc clin Psychol 6:278–296

    PubMed  Google Scholar 

  • Head H (1923) The conception of nervous and mental energy. II. Vigilance: a physiological state of the nervous system. Br J Psychol 14:125–147

    Google Scholar 

  • Heitz C, Descombes JJ, Miller RC, Steclet JC (1986) Alpha-adrenoceptor antagonistic and calcium antagonstic effects of nicergoline in the rat isolated aorta. Eur J Pharmacol 123:279–285

    Article  PubMed  Google Scholar 

  • Herrmann WM (1993) Global benefits of drug treatment in a population of MID patients. Abstract in Progress in the management of age associated memory decline and dementia, Berlin, Germany, September 5

  • Herrmann WM, Kern U, Röhmel J (1986) On the effects of pyritinol on functional deficits of patients with organic mental disorders. Pharmacopsychiatry 19:378–385

    PubMed  Google Scholar 

  • Herrschaft H (1992) Nicergolin. In: Riederer P, Laux G, Pöldinger W (eds) Neuro-Psychopharmaka, Bd 5. Springer, Wien, S 313–324

    Google Scholar 

  • Honigfeld G (1974) NOSIE-30: history and current status of its use in pharmacopsychiatric research. In: Pichot P (ed) Modern problems of pharmacopsychiatry, Vol 7, Psychological measurements in psychopharmacology. Karger, Basel, pp 238–263

    Google Scholar 

  • Iliff LD, Du Boulay GH, Marshall JR, Ross RW, Symon L (1979) Wirkung von Nicergolin auf die Gehirndurchblutung. Arzneimittelforschung 29:1277–1278

    PubMed  Google Scholar 

  • Italian Cooperative Group (1985) Attivita della nicergolina nel deterioramento cerebrale senile: ricerche cliniche controlate verso placebo. Giorn Geront (Suppl) 62:27–43

    Google Scholar 

  • Itil TM, Shapiro DM, Eralp E, Akmann A, Itil KZ, Garbizu C (1985) A new brain function diagnostic unit, including the dynamic brain mapping of computer analyzed EEG, evoked potentials and sleep (a new hardware/software system and its application in psychiatry and psychopharmacology). New Trends Clin Psychiatry 1:107–177

    Google Scholar 

  • Jori MC, De Paolis C, Battaglia A, Ardia A, Praga C (1985) Studio controllato multinazionale: nicergolina nel trattamento sintomatologico dell'invecchiamento cerebrale patologico. Giron Geront 33:1185

    Google Scholar 

  • Kugler J (1988) Electroencephalographic and psychometric measurements during treatment of cerebral insufficiency with nicergoline and co-dergocrine mesylate. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain: an update on nicergoline. Proceedings of an international symposium. Excerpta Medica, Rome, October 1987

    Google Scholar 

  • Lagarde M, Guichardant M, Ghazi I, Dechavanne M (1980) Nicergoline, an anti-aggregating agent which inhibits release of arachnidonic acid from human platelet phospholipids. Prostaglandins 19:551–557

    PubMed  Google Scholar 

  • Le Poncin-Lafitte M, Grosdemouge C, Duterte D, Rapin JR (1984) Simultaneous study of haemodynamic, metabolic and behavioural sequelae in a model of cerebral ischaemia in aged rats: effects of nicergoline. Gerontology 30:109–119

    PubMed  Google Scholar 

  • Maiolo AT, Bianchi Porro G, Galli C, Sessma M (1972) Effects de la nicergoline sur l'hemodynamique cerebrale et la metabolisme ceerebral dans l'hypertension arterielle essentielle et l'arteriosclerose. Clin Ther 62:239–252

    Google Scholar 

  • Martucci N, Manna V, Battaglia A (1985) Eine placebokontrollierte Studie mit Nicergolin an Patienten mit organischem Hirnsyndrom, die an kochleären und vestibulären Störungen leiden. In: Heidrich H (ed) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen. Springer, Berlin, Heidelberg, New York, Tokyo, S 57–66

    Google Scholar 

  • McArthur RA, Cervini MA, Carfagna N (1993) Nicergoline reverses the learning deficits in the radial maze of aged rats. Presented at the 1993 Summer Meeting of the British Association for Psychopharmacology, 25–28 July, Cambridge. Psychopharmacology, Suppl.: A16

  • Meese W, Kluge W, Grumme T, Hopfenmüller W (1980) CT evaluation of the CSF spaces of healthy persons. Neuroradiology 19:131–136

    Article  PubMed  Google Scholar 

  • Moglia A, Arrigo A (1989) Ergot derivatives in the aging brain correlation between EEG spectral analysis and clinical findings. Funct Neurol 4:23–26

    Google Scholar 

  • Moglia A, Arrigo A, Battaglia A, Sacchetti C (1985) Korrelation zwischen computerausgewertetem EEG und klinischen Befunden bei Patienten mit seniler Demenz. In: Heidrich H (ed) Therapeutische Wirksamkeitsnachweise bei nootropen und vasoaktiven Substanzen. Springer, Berlin, Heidelberg, New York, Tokyo, S 49–54

    Google Scholar 

  • Moretti A, Carfagna N, Caccia C, Carpentieri M, Amico A, Marchi G, Trunzo F (1985) Neurochemical effects of ergoline derivatives. In: Heidrich H (ed) Proof of therapeutic effectiveness of nootropic and vasoactive drugs. Springer, Berlin, Heidelberg, New York, Tokyo, pp 103–110

    Google Scholar 

  • Moretti A, Carfagna N, Caccia C, Carpentieri M (1988) Effects of ergolines on neurotransmitter systems in the rat brain. Arch Int Pharmacodyn 294:33–45

    PubMed  Google Scholar 

  • Nicergoline Cooperative Study Group (1990) A double-blind randomized study of two ergot derivatives in mild to moderate dementia. Curr Ther Res 48:597–612

    Google Scholar 

  • Paul A, Chandra P (1979) Einfluß von Nicergolin auf molekularbiologische Prozesse im Gehirn und seine Auswirkung auf die Lernfähigkeit der Ratte. Arzneimittelforschung 29:1238–1251

    PubMed  Google Scholar 

  • Pogliani E, Della Volpe A, Ferrari R, Recalcati P, Praga C (1975) Inhibition of human platelet aggregation by oral administration of nicergoline. A double-blind study. Il Farmaco (Prat) 30:630–640

    Google Scholar 

  • Polich J (1991) P300 in the evaluation of aging and dementia. In: Brunia CHM, Mulder G, Verbaten MN (eds) Event-related brain research. Elsevier, Amsterdam, pp 304–323

    Google Scholar 

  • Rossi AC, Carfagna N, Caccia C, Carpentieri M, Moretti A (1988) Neurochemical effects of ergoline derivatives. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain an update on nicergoline. Proceedings of an international symposium. Excerpta Medica, Rome, October 1987, pp 16–24

    Google Scholar 

  • Rossi A, Battaglia A, Novellini R, Buonamici M, Carfagna N, Orlando N, Pamparana F (1990) Nicergoline: pharmacological properties and clinical studies in aging brain. In: Alan R (ed) Aging brain and dementia: new trends in diagnosis and therapy. Liss, New York, pp 549–576

    Google Scholar 

  • Saletu B (1981) Application of quantitative EEG in measuring encephalotropic and pharmacodynamic properties of antihypoxidotic/nootropic drugs. In: Scientific International Research (ed) Drugs and Methods in C.V.D. Proc Int Cerebrovascular Diseases. Pergamon Press, France, pp 79–115

    Google Scholar 

  • Saletu B (1991) Co-dergocrine type drugs in the pharmacotherapy of mental and cognitive disorders in aging. In: Racagni G, Brunello N, Fukuda T (eds) Biological psychiatry Volume 2. Excerpta Medica, Amsterdam, London, New York, Tokyo, pp 163–165

    Google Scholar 

  • Saletu B (1993) Neurophysiological assessment of efficacy in drug trials with memory disorders. In: Canal N, Hachinski VC, McKhann G, Franceschi M (eds) Guidelines for drug trials in memory disorders. Raven Press, New York, pp 303–331

    Google Scholar 

  • Saletu B (1994) EEG/EP mapping in neurodegenerative and cognitive disorders. In: Racagni G (ed) Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. Int Acad Biomed Drug Res, Vol 7, Karger, Basel, Freiburg, Paris, London, New York, New Delhi, Bangkok, Singapore, Tokyo, Sydney, pp 24–30

    Google Scholar 

  • Saletu B, Grünberger J (1980) Antihypoxidotic and nootropic drugs: Proof of their encephalotropic and pharmacodynamic properties by quantitative EEG investigations. Prog Neuro Psychopharmacol 4:469–489

    Article  Google Scholar 

  • Saletu B, Grünberger J (1985) Memory dysfunction and vigilance: neurophysiological and psychopharmacological aspects. Ann N Y Acad Sci 444:406–427

    PubMed  Google Scholar 

  • Saletu B, Grünberger J, Linzmayer L (1979a) Bestimmung der encephalotropen, psychotropen und pharmakodynamischen Eigenschaften von Nicergolin mittels quantitativer Pharmakoelektroenzephalographie und psychometrischer Analysen. Arzneimittelforschung 29:1251–1261

    PubMed  Google Scholar 

  • Saletu B, Grünberger J, Linzmayer L, Anderer P (1979b) Proof of CNS efficacy and pharmacodynamics of nicergoline in the elderly by acute and chronic quantitative pharmaco-EEG and psychometric studies. In: Tognoni G, Garattini S (eds) Drug treatment in chronic cerebrovascular disorders. Elsevier/North Holland, Biomedical Press, Amsterdam, pp 245–272

    Google Scholar 

  • Saletu B, Anderer P, Kinsperger K, Grünberger J (1987) Topographic brain mapping of EEG in neuropsychopharmacology — part II. Clinical applications (Pharmaco EEG imaging). Meth Find Exp Clin Pharmacol 9 [6]:385–408

    Google Scholar 

  • Saletu B, Anderer P, Paulus E, Grünberger J, Wicke L, Neuhold A, Fischhof PK, Litschauer G, Wagner G, Hatzinger R, Dittrich R (1988) EEG brain mapping in SDAT and MID patients before and during placebo and xantinolnicotinate therapy: reference considerations. In: Samson-Dollfus D, Guieu JD, Gotman J, Etevenon P (eds) Statistics and topography in quantitative EEG. Elsevier, Paris, pp 251–275

    Google Scholar 

  • Saletu B, Grünberger J, Anderer P (1990a) Pharmaco-EEG and brain mapping in cognitive enhancing drugs. Clin Neuropharmacol 13 [Suppl. 2]:575–576

    Google Scholar 

  • Saletu B, Anderer P, Grünberger J (1990b) Topographic brain mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 11:1–22

    Article  PubMed  Google Scholar 

  • Saletu B, Grünberger J, Anderer P (1990c) On brain protection of co-dergocrine mesylate (HydergineR) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol 28:510–524

    PubMed  Google Scholar 

  • Saletu B, Grünberger J, Linzmayer L, Anderer P (1990d) Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. J Neural Transm Park Dis Dement Sect 2:305–325

    PubMed  Google Scholar 

  • Saletu B, Anderer P, Paulus E, Grünberger J, Wicke L, Neuhold A, Fischhof KP, Litschauer G (1991a) EEG brain mapping in diagnostic and therapeutic assessment of dementia. Alzheimer Dis Assoc Disord 5, [Suppl. 1]:57–75

    Google Scholar 

  • Saletu B, Anderer P, Grünberger J, Paulus E, Fischhof PK, Wicke L, Neuhold A (1991b) On diagnosis, differential diagnosis and pharmacotherapy of dementia; mapping of EEG and its correlations to clinical variables. In: Racagni G, Brunello N, Fukuda T (eds) Biological psychiatry Volume 2. Excerpta Medica, Amsterdam, London, New York, Tokyo, pp 398–400

    Google Scholar 

  • Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Böhmer F (1992) EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biol Psychiatry 32:668–681

    Article  PubMed  Google Scholar 

  • Semlitsch H, Anderer P, Saletu B, Resch F, Presslich O, Schuster P (1989) Psychophysiological research in psychiatry and neuropharmacology. I. Methodological aspects of the Viennese Psychophysiological Test-System (VPTS). Meth Find Exp Clin Pharmacol 11:25–41

    Google Scholar 

  • Semlitsch HV, Anderer P, Saletu B, Hochmayer I (1990) Topographic mapping of cognitive event-related potentials in a double-blind, placebo-controlled study with the hemoderivative actovegin in age-associated memory impairment. Neuropsychobiology 24:49–56

    PubMed  Google Scholar 

  • Semlitsch HV, Anderer P, Saletu B (1992) Topographic mapping of long latency “cognitive” event-related potentials (P300): a double-blind, placebo-controlled study with amantadine in mild dementia. J Neural Transm [P-D Sect] 4:319–336

    Google Scholar 

  • Shader RI, Harmatz JS, Salzman C (1974) A new scale for clinical assessement in geriatric populations: Sandoz Clinical Assessment Geriatric (SCAG). J Am Geriatr Soc 22:107–113

    PubMed  Google Scholar 

  • Shintomi K, Egon H, Tanaka T, Itakura T, Yoshimoto K, Matsamoto M, Matsuoka Y (1986) Pharmacological study of nicergoline (I). Protective effect against anoxic brain damages in animals. Folia Pharmacol Jpn 87:445–456

    Google Scholar 

  • Squires KC, Chippendale TJ, Wrege KS, Goodin DS, Starr A (1980) Electrophysiological assessment of mental function in aging and dementia. In: Poon LW (ed) Aging in the 1980s: selected contemporary issues in the psychology of aging. American Psychological Association, Washington, DC, pp 125–134

    Google Scholar 

  • Zappoli R, Versari A, Paganini M, Arnetoli G, Battaglia A, Ardia A, Maniero A (1988) Effect of long-term nicergoline treatment on contingent negative variation activity and clinical status of patients with presenile idiopathic mental deterioration: preliminary findings. In: Kugler J, Agnoli A (eds) Ergot alkaloids and aging brain an update on nicergoline. Proceedings of an international symposium. Excerpta Medica, Rome, October 1987, pp 72–83

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, School of Medicine, University of Vienna, A-1090, Vienna, Austria

    B. Saletu, E. Paulus, L. Linzmayer, P. Anderer, H. V. Semlitsch & J. Grünberger

  2. Institute for Diagnostic Imaging, Rudolfinerhaus, A-1090, Vienna, Austria

    L. Wicke & A. Neuhold

  3. Department of Neurology, School of Medicine, University of Vienna, A-1090, Vienna, Austria

    I. Podreka

Authors
  1. B. Saletu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Paulus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Linzmayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Anderer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. V. Semlitsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Grünberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L. Wicke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Neuhold
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. Podreka
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saletu, B., Paulus, E., Linzmayer, L. et al. Nicergoline in senile dementia of alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 117, 385–395 (1995). https://doi.org/10.1007/BF02246209

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246209

Key words

Search

Navigation